Ardelyx Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Ardelyx (ARDX) Misses Q3 EPS by 22c
November 12, 2015 9:27 AM ESTArdelyx (NASDAQ: ARDX) reported Q3 EPS of ($0.70), $0.22 worse than the analyst estimate of ($0.48).
Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia Initiation of a second Phase 3 clinical trial for tenapanor in IBS-C expected December 2015 Results of a... More



